[ad_1]
The executive director of Sareum Holdings PLC (LON: SAR), Tim Mitchell, has spoken with Andrew Scott, of Proactive London, to discuss some preliminary efficacy data published on a drug that Sareum has helped to develop.
The impact of SRA737 on common chemotherapy called gemcitabine in patients with anobad cancer is particularly noteworthy … "The trial was extremely successful," Mitchell said.
The data comes from a Phase I / II clinical trial undertaken by Sierra Oncology, which licensed this drug candidate under a contract worth up to $ 328.5 million. US dollars, plus royalties.
Source link
